Figure 2.
Susceptibility of AML cell lines to various treatment combinations. Cell viability was determined in AML cell lines MOLM-13 (A), ML-2 (B), OCI-AML3 (C), SKM-1 (D), MOLM-16 (E) and PL-21 (F) after 20 h of treatment with single compounds and in combination with 0.1–0.3 μM PU-H71 (PU) and 0.l μM S63845 (S0.1), 0.1 μM venetoclax (VC0.1), or 1 μM venetoclax (VC1). Significance of differences denoted for p < 0.01 (**); p < 0.001 (***); and p < 0.0001 (****).